Post-Coital Trimethoprim-Sulfamethoxazole Prophylaxis for UTI Prevention
For women with recurrent UTIs temporally related to sexual intercourse, take one single-strength tablet (80 mg trimethoprim/400 mg sulfamethoxazole) or one-half of a double-strength tablet within 2 hours after intercourse.
Dosing Regimen
The appropriate post-coital prophylaxis regimen is:
- Single-strength Bactrim: 1 tablet (80 mg trimethoprim/400 mg sulfamethoxazole)
- OR Double-strength Bactrim: ½ tablet (80 mg trimethoprim/400 mg sulfamethoxazole equivalent)
- Timing: Within 2 hours after sexual intercourse 1
This represents a significantly lower dose than the standard treatment dose (which is 1 double-strength tablet twice daily) 2.
Evidence Supporting Post-Coital Prophylaxis
Post-coital prophylaxis has demonstrated remarkable efficacy in preventing recurrent UTIs in sexually active women. In a landmark study of 25 premenopausal women with recurrent UTIs, post-coital prophylaxis with co-trimoxazole reduced infections from 70 episodes during an 8-month pre-treatment period to only 4 episodes during a 12.5-month treatment period 3. Sexual intercourse was identified as the major triggering factor, with UTIs typically occurring within 24 hours of intercourse 3.
The 2019 AUA/CUA/SUFU guideline explicitly states that "in women who experience UTIs temporally related to sexual activity, antibiotic prophylaxis taken before or after sexual intercourse has been shown to be effective and safe" 1. This intermittent dosing strategy offers the additional benefit of decreased adverse events compared to continuous daily prophylaxis, including reduced gastrointestinal symptoms and vaginitis 1.
Duration and Monitoring
- Duration: Typically 6-12 months with periodic assessment 1
- Clinical practice: Some women continue for years without adverse events, though this lacks evidence-based support 1
- Monitoring: Periodic clinical assessment to determine ongoing need
Important Caveats
Resistance Considerations
The major limitation of TMP-SMX prophylaxis is the development of antimicrobial resistance. Recent data show that prolonged TMP-SMX prophylaxis dramatically reduces susceptibility:
- E. coli susceptibility to TMP-SMX drops from 87.4% to 21.2% in patients on prophylaxis 4
- Cross-resistance develops to other antibiotics including fluoroquinolones and penicillins 4
- Resistance correlates with duration: >406 days of prophylaxis predicts TMP-SMX resistance 4
When TMP-SMX May Not Be Appropriate
According to current guidelines, TMP-SMX should not be used for empirical treatment when local E. coli resistance rates exceed 20% 5, 6. If you practice in an area with high TMP-SMX resistance, consider:
- Alternative post-coital agents: Nitrofurantoin (50-100 mg) or nalidixic acid (500 mg) 3
- First-line alternatives for prophylaxis: Nitrofurantoin or cephalexin 1
Risks and Benefits Discussion
Before prescribing, discuss with patients:
- Benefits: Dramatic reduction in UTI recurrence (up to 94% reduction) 3
- Risks: Potential for serious but rare pulmonary (0.001%) and hepatic (0.0003%) toxicity with nitrofurantoin; gastrointestinal disturbances and rash with TMP-SMX 1
- Resistance: Increased risk of resistant organisms with breakthrough infections 4
Alternative Non-Antibiotic Options
For patients concerned about antibiotic resistance or adverse effects, cranberry prophylaxis may be offered as an alternative, though efficacy is lower than antibiotics 1, 6. D-mannose showed no benefit in recent high-quality trials and should not be recommended 6.